A case report on efficacy of Abound (TM) for anti-EGFR antibody-associated skin disorder in metastatic colon cancer

作者：Matsuhashi Nobuhisa; Takahashi Takao; Nonaka Kenichi; Ichikawa Kengo; Yawata Kazunori; Tanahashi Toshiyuki; Imai Hisashi; Sasaki Yoshiyuki; Tanaka Yoshihiro; Okumura Naoki; Yamaguchi Kazuya; Osada Shinji; Yoshida Kazuhiro^*

来源：World Journal of Surgical Oncology, 2014, 12(1): 35.

DOI：10.1186/1477-7819-12-35

• Abound
• Anti-EGFR antibody
• Skin disorder
• Colon cancer

Background: Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments. %26lt;br%26gt;Case presentation: A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy. During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound (TM), symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued. %26lt;br%26gt;Conclusion: We report that Abound (TM) was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound (TM) could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.

• 出版日期2014-2-11